Sino Biopharmaceutical Limited announced that the latest results of phase II clinical study (NCT05383898) of KRAS G12C Inhibitor "Garsorasib Tablet (D-1553)", which is jointly developed by the Group, will be presented at the Annual Meeting 2024 of American Association for Cancer Research, for the treatment of patient with non-small cell lung cancer ("NSCLC") with KRAS G12C mutation. Title of abstract: Open-label, single-arm, multicenter, phase 2 trial of garsorasib in KRAS G12C-mutated non-small-cell lung cancer.